Patienter med terminal nyresygdom bør nøje overvåges, idet det må forventes, at plasmakoncentrationen af de aktive stoffer i Activelle vil øges.
Patients with terminal renal insufficiency should be closely observed, since it is expected that the level of circulating active ingredients in Activelle will increase.